Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy

• Published in: Journal of the American Heart Association Vol. 7; no. 23; p. e010239
• Main Authors: Mattapally, Saidulu, Pawlik, Kevin M, Fast, Vladimir G, Zumaquero, Esther, Lund, Frances E, Randall, Troy D, Townes, Tim M, Zhang, Jianyi
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 04.12.2018; Wiley
• Subjects: 3‐dimensional culture; class II major histocompatibility class transactivator; CRISPR-Associated Protein 9; CRISPR-Cas Systems; Gene Knockout Techniques; Genes, MHC Class I - genetics; Genes, MHC Class II - genetics; Humans; immunology; Induced Pluripotent Stem Cells - transplantation; Male; Myocytes, Cardiac - transplantation; Original Research; stem cell; Stem Cell Transplantation - methods; Transplantation, Homologous - methods; β2 microglobulin; β2 microglobulin; 3‐dimensional culture; stem cell; immunology; class II major histocompatibility class transactivator
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/jaha.118.010239

Background We aim to generate a line of "universal donor" human induced pluripotent stem cells (hi PSC s) that are nonimmunogenic and, therefore, can be used to derive cell products suitable for allogeneic transplantation. Methods and Results hi PSC s carrying knockout mutations for 2 key components (β2 microglobulin and class II major histocompatibility class transactivator) of major histocompatibility complexes I and II (ie, human leukocyte antigen [HLA] I/ II knockout hi PSC s) were generated using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated protein 9 (Cas9) gene-editing system and differentiated into cardiomyocytes. Pluripotency-gene expression and telomerase activity in wild-type ( WT ) and HLAI / II knockout hi PSC s, cardiomyocyte marker expression in WT and HLAI / II knockout hi PSC -derived cardiomyocytes, and assessments of electrophysiological properties (eg, conduction velocity, action-potential and calcium transient half-decay times, and calcium transient increase times) in spheroid-fusions composed of WT and HLAI / II knockout cardiomyocytes, were similar. However, the rates of T-cell activation before (≈21%) and after (≈24%) exposure to HLAI / II knockout hi PSC -derived cardiomyocytes were nearly indistinguishable and dramatically lower than after exposure to WT hi PSC -derived cardiomyocytes (≈75%), and when WT and HLAI / II knockout hi PSC -derived cardiomyocyte spheroids were cultured with human peripheral blood mononuclear cells, the WT hi PSC -derived cardiomyocyte spheroids were smaller and displayed contractile irregularities. Finally, expression of HLA -E and HLA -F was inhibited in HLAI / II knockout cardiomyocyte spheroids after coculture with human peripheral blood mononuclear cells, although HLA -G was not inhibited; these results are consistent with the essential role of class II major histocompatibility class transactivator in transcriptional activation of the HLA -E and HLA-F genes, but not the HLA -G gene. Expression of HLA -G is known to inhibit natural killer cell recognition and killing of cells that lack other HLAs. Conclusions HLAI / II knockout hi PSC s can be differentiated into cardiomyocytes that induce little or no activity in human immune cells and, consequently, are suitable for allogeneic transplantation.